期刊文献+

高剂量重组人红细胞生成素冲击治疗恶性肿瘤贫血的临床应用及护理 被引量:1

Clinal application and nursing of high-dose recombinant human erythropoietin in treatment of a-nemic patients with malignancies
原文传递
导出
摘要 目的观察高剂量重组人红细胞生成素(RHEpo)冲击治疗恶性肿瘤贫血的临床疗效及不良反应。方法将86例恶性肿瘤贫血患者随机分为对照组(RHEpo1万U,每周3次,共6周)与高剂量组(RHEpo4万U/次,第1、3天,RHEpo2万U/次,第6、9、12、15、18、21、24天)。治疗期间加强患者心理护理,合理用药,严密观察病情,及时处理并发症。所有患者共观察6周,每2周进行1次疗效评价,评价指标包括患者的血红蛋白值、有效率、输血率、停药者比率及药物的不良反应。结果对照组4周后血红蛋白值明显升高,高剂量组治疗2周后血红蛋白值明显升高;高剂量组的4、6周血红蛋白值均高于对照组(P〈0.05);高剂量组的2、4、6周有效率分别为40.5%、54.8%、71.4%,高于对照组的19%、28.6%、50.0%(P〈0.05);两组输血率及不良反应率比较差异无统计学意义(P〉0.05)。结论高剂量RHEpo冲击治疗恶性肿瘤贫血的疗效优于常规剂量法,不良反应无明显增加,合理护理是RHEpo充分发挥疗效的关键。 Objective To study the clinical effect and side effect of high-dose recombinant hu- man erythropoietin (RHEpo)on anemic patients with malignancies. Methods Eighty-six anemic patients with malignancies were randomly divided into matched group (rhEPO 10 000 U were administered three times weekly for up to six weeks) or tJigh-dose group( the specific use for the first 1,3 days for erythropoi- etin 40 000U, and then in the first:6, 9,12,15,18,21,24 days given erythropoietin 20 000U every day). Strengthen psychological nursing, rational use of drugs, condition observation, management of complications during the course of treatment. The patients were observed for 6 weeks, and evaluated ev- ery 2 weeks. The evaluation indexes including hemoglobin value, efficient rate, blood transfusion rate, the ratings and adverse reaction. Results Hemoglobin level of high-dose group increased significantly after treatment of 2 weeks, while that of matched group increased significantly after treatment of 4 weeks. The main hemoglobin level in high-dose group was higher than those in matched group after treatment of 4 and 6 weeks( P 〈 0. 05). The effect rates of 2,4,6 weeks were 40. 5% ,54. 8% ,71.4% respectively in high-dose group, higher than 19% ,28.6% ,50. 0% respectively in matched group( P 〈0.05). There were no significant differences in side effect and transfusion rate between the two groups ( P 〉 0. 05 ). Conclusions The effect of high-dose RHEpo is better than RHEpo with common doses on anemic pa- tients with malignancies. There is no difference in side effect between the two groups. Reasonable care plays an important role in the curative effect of RHEpo.
出处 《中国实用医刊》 2013年第4期95-97,共3页 Chinese Journal of Practical Medicine
关键词 重组人红细胞生成素 肿瘤 贫血 Recombinant human erythropoietin Neoplasm Anemia
作者简介 通信作者:孙衍伟,E—mail:sun721688@163.com
  • 相关文献

参考文献10

  • 1Patton J,Kuzur M,Liqqett W. Epoetin alfa 60000U once weekly followed by 120000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy[J].Oncologist(The),2004,(01):90-96.
  • 2Cortesi E,Mancuso A,De Pasquale Ceratti A. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy[J].Oncologist(The),2004,(04):459-468.
  • 3Rizzo JD,Lichtin AE,Woolf SH. Use of epoetin in patients with cancer:evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology[J].Journal of Clinical Oncology,2002,(19):4083-4107.
  • 4Ariganello O,Mancuso A,Di Molfetta M. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer[J].Lung Cancer,2004,(01):119-124.doi:10.1016/j.lungcan.2004.03.017.
  • 5Santini D,Vincenzi B,La Cesa A. A new dose-intense epoetin alfa regimen effective in anemic cancer patients receiving chemotherapy:an open-label,non randomized,pilot study[J].Anticancer Research,2005,(1B):669-674.
  • 6李睿,吴晴,陆舜,张凤春,金冶宁,王杰军.重组人红细胞生成素-α治疗恶性实体瘤相关贫血的临床研究[J].肿瘤,2008,28(2):132-135. 被引量:10
  • 7Fujisaka Y,Sugiyama T,Saito H. Randomised,phase Ⅲ trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation[J].British Journal of Cancer,2011,(09):1267-1272.
  • 8Durmaz O,Demirkaya M,Sevinir B. Recombinant human erythropoietin β:the effect of weekly dosing on anemia,quality of life,and longterm outcomes in pediatric cancer patients[J].Pediatric Hematology and Oncology,2011,(06):461-468.
  • 9廉秀花,杨美功.低分子肝素皮下注射方法的改进[J].护士进修杂志,2007,22(1):90-91. 被引量:30
  • 10徐佳美,郭艳香,范汝艳,黄兴华.肘关节伸侧皮下注射重组人红细胞生成素治疗贫血的观察[J].护理与康复,2007,6(2):75-77. 被引量:6

二级参考文献13

  • 1张华,倪琴,吴歆华.改良低分子肝素注射手法减少皮下淤血的护理观察[J].解放军护理杂志,2005,22(6):96-97. 被引量:19
  • 2滕杰,丁小强,王梅,陈香美,彭立人,汪关煜,顾勇.国产重组人红细胞生成素治疗肾性贫血的疗效和安全性[J].中国临床药学杂志,2005,14(5):301-304. 被引量:7
  • 3RALPH B, IMTIAZ A M, VINAY R, et al. Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced anemia[ J]. Oncologist,2006,11 (4) : 409-417.
  • 4IAN Q, MICHAEL K, FELIX C, et al. Patients previously transfused or treated with epoetin alfa at low baseline hemoglobin are at higher risk for subsequent transfusion : an integrated analysis of the canadian experience [ J ]. Oncologist, 2006, 11 ( 1 ) : 73-82.
  • 5KOTASEK D, STEGER G, FAUGHT W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study [ J ]. Eur J Cancer,2003, 39 (14) : 2026-2034.
  • 6VADHAN-RAJ S, MIRTSCHING B, CHARU V, et al. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks [ J ]. J Support Oncol , 2003,1 (2) : 131-138.
  • 7GABRILOVE J L, CLEELAND C S, LIVINGSTON R B,et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing[ J ]. J Clin Oncol,2001,19 ( 11 ):2875-2882.
  • 8BOHLIUS J, WILSON J, SEIDENFELD J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients [ J ]. J Natl Cancer lnst, 2006, 98 (10) : 708-714.
  • 9BENNETT C L, COURNOYER D, CARSON K R, et al. Longterm outcome of individuals with pure red cell aplasia and anitery- thropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the research on adverse drug events and reports (RADAR) project[ J]. Blood,2005,106(10) : 3343-3347.
  • 10赵秀丽,胡大一.抗凝制剂——低分子肝素的研究进展[J].心血管病学进展,1998,19(6):321-322. 被引量:19

共引文献42

同被引文献11

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部